Efficacy and Recovery in BPH Surgery: Insights from Transurethral Bipolar Enucleation
Abstract
Background: Benign prostatic hyperplasia (BPH) is a prevalent condition among older men, often resulting in bladder obstruction. Goal: This study focuses on evaluating the efficacy and recovery associated with Transurethral Bipolar Enucleation and Resection of the Prostate (TBERP) for treating BPH in patients with large prostates (>80 g). Patients and Methods: A randomized prospective clinical trial was conducted on BPH patients over 50 years old with a prostate volume >80 mL, maximum flow rate (Qmax) >15 mL/s, and International Prostate Symptom Score (IPSS) >8, meeting established surgical indications. Patients underwent TBERP, with intraoperative blood loss, operation time, resected prostatic tissue weight, postoperative catheterization, and hospital stay period being recorded. Additionally, patients were assessed for IPSS, post-voiding residual urine, prostate volume, and complications (including urinary retention, urinary tract infection, irritative symptoms, urinary incontinence, urethral stricture, and bladder neck contracture) over a three-month follow-up period. Results: The study enrolled 32 patients with a mean age of 62.63 years. TBERP demonstrated effective outcomes with minimal complications during the three-month follow-up period. The mean catheterization period was 5.09 days, and the mean hospital stay was 2.13 days. The mean operative time was 121.88 minutes, and the mean weight of resected prostatic tissue was 43.94 g. Conclusion: TBERP is a safe and…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 32 participants or records.
Read the paper
Related studies
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives-
- Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
- Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer
- Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health
- Long-term outcomes after treatment with Optilume BPH: Four-year results from the EVEREST study
- Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.